BioSenic provides further information on its restructuring plan

  PRESS RELEASE - PRIVILEGED INFORMATION

Mont-Saint-Guibert, Belgium, 12 April 2024, 12:00 CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, as part of the global restructuring plan announced on 11 April 2024, provides information on (i) the Company's current debt position and the potential impact of the plan on this position and (ii) links to the Company's website to consult the conversion terms and conditions offered to holders of convertible bonds (excluding Global Tech Opportunities 15) as part of the plan.

The impact that the global restructuring plan could have on BioSenic's debt position is as follows:

		Due	Paid within 5 years	31/12/2030 + 24 months
Extraordinary lease		€               61 211,77	€                               61 211,77
Ordinary		€          2 750 655,64	€                             137 532,78
Strategic		€             223 869,65	€                             201 482,69
Workers accessories		€                 8 736,45	€                                 8 649,09
Interco		€                 8 736,45	€                                    436,82
Very useful		€             344 209,67	€                             172 104,84
Shareholder		€             124 912,50	0
Non-convertible bonds		€          4 121 800,00		€                                  4 121 800,00
Convertible bonds		€          2 000 000,00		€                                  2 000 000,00
Loan		€          1 500 000,00		€                                  1 500 000,00
Bullet		€          8 487 200,00		€                                  8 487 200,00
Sub-total allocated		€       19 631 332,13	€                             581 417,99	€                                16 109 000,00
Unallocated	Converted	€          2 400 000,00
Total		€       22 031 332,13	€                             581 417,99	€                                16 109 000,00

It should be noted, however, that this table only shows the potential impact of the plan if it were to be accepted as it stands and does not take into account any new debt that the Company may incur in the future. This is also a non-consolidated view of the Company, as the debt of the subsidiary Medsenic is not taken into account.